Quote | Taysha Gene Therapies Inc. (NASDAQ:TSHA)
Last: | $2.16 |
---|---|
Change Percent: | -1.77% |
Open: | $2.3 |
Close: | $2.16 |
High: | $2.31 |
Low: | $2.14 |
Volume: | 1,942,455 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Taysha Gene Therapies Inc. (NASDAQ:TSHA)
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...
2024-06-26 09:32:05 ET More on Taysha Gene Therapies Taysha Gene Therapies: Latest Rett Data Checks Momentum, Road Ahead Rocky Taysha Gene Therapies stock slides after commence securities offering to raise $75 million Seeking Alpha’s Quant Rating on Taysha Gen...
Message Board Posts | Taysha Gene Therapies Inc. (NASDAQ:TSHA)
Subject | By | Source | When |
---|---|---|---|
Between November 2022 and Feb 9th FMR LLC | ErnieBilco | investorshub | 02/09/2023 7:20:47 PM |
Perspective | conix | investorshub | 02/06/2023 3:04:15 PM |
What a buying opportunity here this morning. | ErnieBilco | investorshub | 02/01/2023 3:38:30 PM |
Grabbed more earlier today after doing further due | scotsand | investorshub | 11/16/2022 3:50:14 PM |
14,000 SHARE BUY @2.21 $HUGE BUYS COMING IN $$$$$$$$$$$$$$$$$$$$$$$ | 1hot toddy | investorshub | 11/15/2022 7:29:00 PM |
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
Taysha Gene Therapies Inc. Website:
2024-06-26 17:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for TSHA on June 26, 2024 04:10PM ET. TSHA was trading at $2.04 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 6 - Buy, 1 - Hol...
DALLAS, June 26, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an ...
DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commen...